NewAmsterdam Pharma is a clinical-stage biopharmaceutical company focused on oral therapies for cardiometabolic disease. Its lead programs center on CETP inhibition—most notably obicetrapib—to lower LDL cholesterol and address residual cardiovascular risk beyond standard lipid treatments. The company targets patients with dyslipidemia who need additional lipid lowering on top of or instead of existing options. Development is oriented toward large primary-care and specialty cardiology markets rather than rare-disease niches.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 19.1 | — | -17.4 | — |
| Q3 2025 | 0.3 | — | -72 | — |
| Q4 2025 | 0 | — | -74.9 | — |
| Q1 2026 | 3 | — | -48.4 | — |
| Q2 2026 | 3.7 | -80.7% | -64.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Chagee Holdings Limited (CHA), Blackbaud, Inc. (BLKB), Visteon Corporation (VC), Telesat Corporation (TSAT), Banner Corporation (BANR), Peloton Interactive, Inc. (PTON)